A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

NCT07678684 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Adult

Interventions

DRUG: HF1K16

Sponsor

HighField Biopharmaceuticals Corporation